Atriva Therapeutics

@AtrivaTx

Clinical stage biopharmaceutical company developing host-targeting inhibitors against respiratory viral infections.

Tübingen, Germany
Vrijeme pridruživanja: listopad 2019.

Tweetovi

Blokirali ste korisnika/cu @AtrivaTx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AtrivaTx

  1. prije 2 sata

    “. is working on ways to block viral activity. Dr. Lichtenberger, CEO, told that the company’s approach involved inhibiting the pathway which is used by RNA viruses like when they replicate within cells.”

    Poništi
  2. proslijedio/la je Tweet

    How credible do you think the current reports regarding the Novel Acute Respiratory Disease?

    Poništi
  3. 2. velj

    As the spreads, fear is fueling racism and - CNN. This is not the they. We need to fight and not against each other.

    Poništi
  4. proslijedio/la je Tweet

    China initially put secrecy and order ahead of confronting the coronavirus. The New York Times reconstructed the crucial 7 weeks when it grew into a crisis.

    Poništi
  5. 31. sij

    Knowledge and science have no borders. Scientist and experts off all world are working together to find a solution to beat . Germans scientist are also contributing working and sharing results.

    Poništi
  6. 31. sij

    Die von . entwickelte Substanz blockiert die Kommunikation zwischen Viren und Körperzellen und kann so effektiv gegen ein breites Spektrum von Viren eingesetzt werden. Atriva ist es gelungen, die Vermehrung von SARS und eines in Zellkulturen zu verhindern.

    Poništi
  7. 30. sij

    Prof. Ludwig ist ein großartiger Wissenschaftler und Kollaborator. Seit Jahren arbeiten wir erfolgreich mit ihm zusammen, um gegen zu entwickeln.

    Poništi
  8. proslijedio/la je Tweet
    29. sij

    Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany

    Poništi
  9. 29. sij

    The world is under virus attack, but German scientists are already on the move. spoke with Prof. Dr. Ludwig, developer of ’ host-targeting candidate, , about pandemic threats like , SARS, MERS and .

    Poništi
  10. 15. sij

    The 3rd and last conference during the ’s San Francisco tour is the 15th Non-Dilutive Funding Summit . Meet our representatives to learn more about our potential in the development of host-targeting therapies.

    Poništi
  11. 14. sij

    We look forward to telling you more about , our host-targeting approach to treat , at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.

    Poništi
  12. proslijedio/la je Tweet
    13. sij

    'Good Morning from 2020! is on site in San Francisco, excited for three days of presentations, panels and 1X1 meetings at one of the industry's leading investor conferences. We're looking forward to meeting you!

    Poništi
  13. 13. sij

    Learn more about ’s host-targeting therapy candidate against , hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at . Join us at 11:30, Franciscan D.

    Poništi
  14. 9. sij

    kicks off the new year by travelling to to participate in three conferences. Dr. Lichtenberger, CEO, Dr. Wallasch, COO, and Dr. Björn Cochlovius, VP BD, will represent the Company and be available for networking and one-on-ones.

    Poništi
  15. proslijedio/la je Tweet
    23. pro 2019.

    During this holiday season relax and enjoy the time with family and friends and don't forget to register for in : January 13-15, 2020. . will be on site to support you! We hope to see you there!

    Poništi
  16. 20. pro 2019.

    is always lurking, especially during the winter season, which impairs our immune system. At , we are developing a unique portfolio of broadly active and efficacious antiviral drugs. Stay warm and enjoy the . and from Atriva.

    Poništi
  17. 19. pro 2019.

    ! ’s co-founder and scientific advisor Prof. Ludwig, head of the Virology Institute at is prominently featured in an interesting article on the by : .

    Poništi
  18. proslijedio/la je Tweet
    5. pro 2019.

    . invites journalists to attend 2020. We will be on site to support media and partnering meetings and to organize interviews. Do not hesitate to contact us. See you in San Francisco!

    Poništi
  19. 20. stu 2019.

    ’s strategy and product candidate “may revolutionize treatment of and other severe respiratory viral infections” and be “a quantum leap in respiratory therapies”. Learn more in the article by

    Poništi
  20. 11. stu 2019.

    Learn more about against and respiratory in the presentation of Dr. Rainer Lichtenberger, our CEO, today at 5.45 PM during the “Infectious Disease Company Presentations” section Level 1/Hall B1/Room 7

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·